CHB患者血清miRNA-122和miRNA-155检测的价值

doi:10.3969/j.issn.1673-8640.2019.08.004

检验医学 ›› 2019, Vol. 34 ›› Issue (8): 691-695.DOI: 10.3969/j.issn.1673-8640.2019.08.004

CHB患者血清miRNA-122和miRNA-155检测的价值

王颖智, 刘华, 王文涓, 高锋, 杨翠霞()

上海交通大学附属第六人民医院检验科,上海 200233

收稿日期:2018-12-25 出版日期:2019-08-30 发布日期:2019-08-27
作者简介:null
作者简介：王颖智,女,1982年生,硕士,主管技师,主要从事乙型肝炎免疫相关的研究。刘华,女,1976年生,学士,主管技师,主要从事临床免疫实验室检测相关的研究。王颖智和刘华对本研究具有同等贡献,并列为第一作者。
基金资助:
上海青年临床医技人才（临床检验专业）培养资助计划（沪医卫基[2016]04）

Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B

WANG Yingzhi, LIU Hua, WANG Wenjuan, GAO Feng, YANG Cuixia()

Department of Clinical Laboratory,Shanghai Jiaotong University Affiliated Sixth People's Hospital,Shanghai 200233,China

Received:2018-12-25 Online:2019-08-30 Published:2019-08-27

摘要/Abstract

摘要：

目的探讨慢性乙型肝炎（CHB）患者血清微小RNA（miRNA）-122和miRNA-155水平与乙型肝炎病毒（HBV）复制情况、抗病毒治疗及耐药基因突变等的关系。方法检测35例CHB患者和24名体检健康者的血清miRNA-122、miRNA-155、HBV DNA载量、乙型肝炎血清学标志物[乙型肝炎表面抗原（HBsAg）、乙型肝炎表面抗体（HBsAb）、乙型肝炎e抗原（HBeAg）、乙型肝炎e抗体（HBeAb）、乙型肝炎核心抗体（HBcAb）]、丙氨酸氨基转移酶（ALT）、HBV耐药基因突变、HBV基因型等指标。采用Spearman相关分析评估各项目间的相关性。结果 CHB组血清miRNA-122相对表达量明显高于正常对照组（P<0.05）,血清miRNA-155表达量明显低于正常对照组（P<0.05）。根据是否使用核苷类药物进行抗病毒治疗将CHB患者分为治疗组（17例）和非治疗组（18例）。Spearman相关分析结果显示,非治疗组血清miRNA-122相对表达量与乙型肝炎血清学标志物模式呈正相关（r=0.73,P=0.00）,与HBV DNA载量及HBsAg、HBeAg、ALT水平均呈正相关（r值分别为0.69、0.74、0.53、0.48,P<0.05）,与年龄呈负相关（r=-0.58,P=0.01）。治疗组血清miRNA-122相对表达量与HBsAg水平呈正相关（r=0.54,P<0.05）,血清miRNA-155相对表达量与HBV DNA载量呈负相关（r=-0.54,P<0.05）。根据是否检测到HBV DNA将治疗组CHB患者分为HBV DNA阴性组和HBV DNA阳性组,HBV DNA阳性组血清miRNA-155相对表达量明显低于HBV DNA阴性组（P<0.05）。结论 CHB患者血清miRNA-122与乙型肝炎相关指标HBV DNA、HBsAg、HBeAg、ALT密切相关,或可用于评价HBV复制情况和CHB的严重程度;血清miRNA-155与HBV DNA载量密切相关,或可用于预测和评价CHB的疗效。

关键词: 微小RNA-122, 微小RNA -155, 慢性乙型肝炎

Abstract:

Objective To analyze the relationship between serum levels of microRNA-122（miRNA-122）,microRNA-155（miRNA-155） and viral replication,antiviral therapy and drug resistance gene mutation in patients with chronic hepatitis B（CHB）. Methods A total of 24 healthy subjects and 35 patients with CHB were enrolled. Serum levels of miRNA-122,miRNA-155,hepatitis B virus（HBV） DNA load,hepatitis B surface antigen（HBsAg）,hepatitis B surface antibody（HBsAb）,hepatitis B e antigen（HBeAg）,hepatitis B e antibody（HBeAb）,hepatitis B core antibody（HBcAb）,alanine aminotransferase（ALT）,the drug resistance gene mutation of HBV and the genotyping of HBV were determined,and the correlations were analyzed. Results In CHB group,serum level of miRNA-122 was higher,and serum level of miRNA-155 was lower than those in healthy control group（P<0.05）. Spearman correlation analysis showed that the relative expression of serum miRNA-122 in CHB patients without antiviral treatment with nucleoside drugs（non-treatment group,18 cases） was positively correlated with the pattern of hepatitis B serological markers（r=0.73,P=0.00）,it was positively correlated with HBV DNA load,HBsAg,HBeAg and ALT in non-treatment group（r=0.69,0.74,0.53 and 0.48,respectively,P<0.05）,and it was negatively with age（r=-0.58,P=0.01）. In treatment group（17 cases）,the relative expression of serum miRNA-122 was positively correlated with the level of HBsAg（r=0.54,P<0.05）,while the relative expression of serum miRNA-155 was correlated with HBV DNA load（r=-0.54,P<0.05）. CHB group was subclassified into HBV DNA negative group and HBV DNA positive group according to whether HBV DNA was detemined or not. The relative expression of serum miRNA-155 in HBV DNA positive group was lower than that in HBV DNA negative group（P<0.05）. Conclusions Serum miRNA-122 is correlated with HBV DNA load,HBsAg,HBeAg and ALT,and it may predict viral replication and severity of CHB. Serum miRNA-155 may be valuable in predicting and evaluating the therapeutic effect of CHB.

Key words: MicroRNA-122, MicroRNA-155, Chronic hepatitis B

中图分类号:

R446.1

王颖智, 刘华, 王文涓, 高锋, 杨翠霞. CHB患者血清miRNA-122和miRNA-155检测的价值[J]. 检验医学, 2019, 34(8): 691-695.

WANG Yingzhi, LIU Hua, WANG Wenjuan, GAO Feng, YANG Cuixia. Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B[J]. Laboratory Medicine, 2019, 34(8): 691-695.

图/表 2

图1 CHB组与正常对照组血清miRNA-122和miRNA-155相对表达量的比较注：（a）CHB组与正常对照组血清miRNA-122相对表达量的比较;（b）CHB组与正常对照组血清miRNA-155相对表达量的比较;与正常对照组比较,*P<0.05

图2 治疗组不同HBV DNA载量的CHB患者血清miRNA-122和miRNA-155相对表达量的变化注：（a）HBV DNA阳性组与HBV DNA阴性组血清miRNA-122相对表达量的比较;（b）HBV DNA阳性组与HBV DNA阴性组miRNA-155相对表达量的比较;与HBV DNA阴性组比较,*P<0.05

参考文献 9

[1]	LATERZA O F,LIM L,GARRETT-ENGELE P W,et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury[J]. Clin Chem,2009,55(11):1977-1983.
[2]	中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎诊断标准(2015年版)[J]. 中西医结合肝病杂志,2015,25(6):384.
[3]	NAKAMURA M,KANDA T,JIANG X,et al.Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis[J]. PLoS One,2017,12(5): e0177302.
[4]	TAT TRUNG N,DUONG D C,TONG H V,et al.Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma[J]. PLoS One,2018,13(4):e0196081.
[5]	QIAO D D,YANG J,LEI X F,et al.Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features[J]. Eur Rev Med Pharmacol Sci,2017,21(4):742-747.
[6]	AKUTA N,SUZUKI F,KOBAYASHI M,et al.Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance[J]. J Med Virol,2018,90(10):1586-1592.
[7]	SARKAR N,PANIGRAHI R,PAL A,et al.Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes[J]. J Viral Hepat,2015,22(10):817-827.
[8]	YU S L,DENG H,LI X H,et al.Expression of microRNA-155 is downregulated in peripheral blood mononuclear cells of chronic hepatitis B patients[J]. Hepat Mon, 2016,16(1):e34483.
[9]	BALA S,TILAHUN Y,TAHA O,et al.Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection[J]. J Transl Med,2012,10:151.

[1]	刘洋, 耿坤静, 栗红江, 石昊曦, 陈思思. 25（OH）D₃与肝脏炎症分期和抗病毒疗效的相关性分析[J]. 检验医学, 2022, 37(7): 628-631.
[2]	马艳婷, 苏曦, 黄斐, 王梦娴, 沈敏娜, 张春燕, 王蓓丽, 潘柏申, 郭玮. HBV RNA检测在慢性乙型肝炎中的临床价值[J]. 检验医学, 2022, 37(1): 72-77.
[3]	李彩东, 张旭强, 雷志萍, 陈俏丽, 陈璐, 田鹏飞, 段正军. IL-1β、IL-6、TNF-α在慢性HBV感染不同临床病程中的临床意义[J]. 检验医学, 2021, 36(8): 790-794.
[4]	程惠芬. 血清P-选择素、ICAM-1、IL-17A水平在HBV感染相关疾病中的临床价值[J]. 检验医学, 2021, 36(6): 646-649.
[5]	刘婷婷, 林玉婷, 米拉, 李晓勤. 血清IL-33水平及其基因多态性与HBV感染临床转归的相关性[J]. 检验医学, 2021, 36(11): 1101-1105.
[6]	郭平, 庄丽花, 陈骊婷, 王剑飚, 吴建峰. 平均红细胞体积、红细胞分布宽度和血清淀粉样蛋白A监测慢性乙型肝炎进展的价值初探[J]. 检验医学, 2020, 35(11): 1153-1157.
[7]	俞晓春, 胡旭姣, 章家青, 国蕾蕾. HA、Ⅳ-C、APRI及Fib-4对乙型肝炎后肝纤维化的诊断效果[J]. 检验医学, 2019, 34(6): 539-542.
[8]	高万芹, 张勤, 朱琳, 吴斌, 何文涛, 张庭禄, 赵长新. 慢性乙型肝炎患者HBV基因型分析及对6种核苷类药物的耐药性[J]. 检验医学, 2019, 34(11): 994-997.
[9]	郭静, 李从荣. 慢性乙型肝炎患者HBV DNA载量与血小板及APRI的相关研究[J]. 检验医学, 2018, 33(4): 321-323.
[10]	侯丽, 于璐, 牛瑶, 张媛, 王亮. 非创伤性诊断模型在慢性乙型肝炎患者肝纤维化中的应用[J]. 检验医学, 2018, 33(10): 888-893.
[11]	梁冬雨, 侯彦强, 娄晓丽. HBV相关肝炎、肝硬化及肝癌患者DcR3的表达及其与Fas的关系[J]. 检验医学, 2017, 32(3): 178-181.
[12]	葛丹红, 徐翀, 姚玉峰. 慢性乙型肝炎患者外周血细胞毒T细胞表面NK相关受体的表达[J]. 检验医学, 2017, 32(2): 108-113.
[13]	冯玥玥, 王蕾. 慢性乙型肝炎患者中医辨证与实验室指标相关性的研究进展[J]. 检验医学, 2016, 31(2): 147-152.
[14]	杜振华, 鲍布和, 王仁杰, 任党利, 张明华, 刘冀琴. 外周血DNT细胞及T细胞亚群变化与乙型肝炎慢性化的相关性研究[J]. 检验医学, 2015, 30(7): 723-727.
[15]	刘伟平, 易琴, 殷明刚. ALT和HBV DNA联合诊断e抗原阴性的慢性活动性乙型肝炎诊断界值的建立及评价[J]. 检验医学, 2014, 29(5): 483-487.

CHB患者血清miRNA-122和miRNA-155检测的价值

Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 9

相关文章 15

编辑推荐

Metrics